Leo gambles on partner’s skin cancer drug even though option agreement is not yet settled

Although Leo Pharma has not yet made a final decision about whether to purchase its partner, Pellepharm - which is behind the company’s first venture into rare skin diseases – the Danish company has already sent more employees to the US to help with the launch.

Photo: Peter Klint

If everything goes well with the development of Pellepharm’s treatment for Gorlin syndrome, patidegib, the company will launch the drug in 2022. With this time frame in mind, the company’s Danish partner, Leo Pharma, has now assembled a team to help the small, San Francisco-based company with its launch plans.

This is despite the fact that Leo Pharma has not yet decided whether to use the option agreement it has with Pellepharm to buy the company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs